Traders sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Friday. $84.10 million flowed into the stock on the tick-up and $170.26 million flowed out of the stock on the tick-down, for a money net flow of $86.16 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.75 for the day and closed at $73.77
A number of research firms recently issued reports on GILD. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Mizuho raised their price target on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann restated a “hold” rating and set a $74.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 25th. Finally, Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $85.92.
The firm has a market capitalization of $96,363.46, a price-to-earnings ratio of 7.70, a PEG ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 4.74.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the company posted $2.75 EPS. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.
In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.11, for a total value of $6,094,705.63. Following the sale, the insider now owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,269,486 over the last 90 days. 1.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seizert Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Investment Centers of America Inc. increased its stake in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after acquiring an additional 1,958 shares during the last quarter. Fagan Associates Inc. increased its stake in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after acquiring an additional 845 shares during the last quarter. Capital Asset Advisory Services LLC acquired a new position in shares of Gilead Sciences in the second quarter worth $875,000. Finally, First PREMIER Bank increased its stake in shares of Gilead Sciences by 9.0% in the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock worth $1,524,000 after acquiring an additional 1,787 shares during the last quarter. Institutional investors own 74.38% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/11/12/traders-sell-shares-of-gilead-sciences-inc-gild-on-strength-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.